

Contents

PART I

1 Leukemia

Deborah Tomlinson

1.1 Acute Lymphoblastic Leukemia	2
1.1.1 Epidemiology	2
1.1.2 Etiology	4
1.1.2.1 Genetic Factors	4
1.1.2.2 Environmental Factors	4
1.1.3 Molecular Genetics	6
1.1.4 Symptoms and Clinical Signs	7
1.1.5 Diagnostics	8
1.1.6 Staging and Classification	8
1.1.6.1 Risk Classification	8
1.1.6.2 Cell Morphology	10
1.1.6.3 Cytochemistry	10
1.1.6.4 Immunophenotyping	10
1.1.6.5 Cytogenetics	11
1.1.7 Treatment	12
1.1.7.1 Induction	12
1.1.7.2 Intensification/Consolidation	13
1.1.7.3 CNS-directed Therapy	13
1.1.7.4 Maintenance/Continuing Treatment	14
1.1.7.5 Allogeneic Stem Cell Transplant	14
1.1.8 Prognosis	15
1.1.9 Follow-up	15
1.1.10 Future Perspectives	15
1.2 Acute Myeloid Leukemia	16
1.2.1 Epidemiology	16
1.2.2 Etiology	16
1.2.2.1 Genetic Factors	16
1.2.2.2 Environmental Factors	16
1.2.3 Molecular Genetics	16
1.2.4 Symptoms and Clinical Signs	17
1.2.5 Diagnostics	17
1.2.6 Staging and Classification	17
1.2.7 Treatment	19
1.2.8 Prognosis	19
1.2.9 Follow-up	19
1.2.10 Future Perspectives	20

1.3 Chronic Myeloid Leukemia	20
1.3.1 Epidemiology and Etiology	20
1.3.2 Molecular Genetics	20
1.3.3 Symptoms and Clinical Signs	20
1.3.4 Diagnostics	21
1.3.5 Treatment	21
1.3.6 Prognosis	21
1.3.7 Future Perspectives	21
1.4 Juvenile Myelomonocytic Leukemia	21
1.5 Langerhans Cell Histiocytosis	22
References	23

2 Solid Tumors

Eleanor Hendershot

2.1 Hodgkin's Disease	26
2.1.1 Epidemiology	26
2.1.2 Etiology	27
2.1.3 Molecular Genetics	27
2.1.4 Symptoms and Clinical Signs	27
2.1.5 Diagnostics	27
2.1.6 Staging and Classification	28
2.1.7 Treatment	28
2.1.8 Prognosis	29
2.1.9 Follow-up	30
2.1.10 Future Perspectives	30
2.2 Non-Hodgkin's Lymphoma	30
2.2.1 Epidemiology	30
2.2.2 Etiology	30
2.2.3 Molecular Genetics	31
2.2.4 Symptoms and Clinical Signs	31
2.2.5 Diagnostics	31
2.2.6 Staging and Classification	34
2.2.7 Treatment	35
2.2.8 Prognosis	36
2.2.9 Follow-up	36
2.2.10 Future Perspectives	37

2.3 Ewing's Sarcoma Family of Tumors	37	2.8 Retinoblastoma	62
2.3.1 Epidemiology	37	2.8.1 Epidemiology	62
2.3.2 Etiology	37	2.8.2 Etiology	62
2.3.3 Molecular Genetics	37	2.8.3 Molecular Genetics	62
2.3.4 Symptoms and Clinical Signs	38	2.8.4 Signs and Symptoms	62
2.3.5 Diagnostics	38	2.8.5 Diagnostics	63
2.3.6 Staging and Classification	38	2.8.6 Staging and Classification	63
2.3.7 Treatment	39	2.8.7 Treatment	65
2.3.8 Prognosis	40	2.8.8 Prognosis	66
2.3.9 Follow-up	40	2.8.9 Follow-up	66
2.3.10 Future Perspectives	41	2.8.10 Future Directions	66
2.4 Osteosarcoma	41	2.9 Rhabdomyosarcoma	66
2.4.1 Epidemiology	41	2.9.1 Epidemiology	66
2.4.2 Etiology	41	2.9.2 Etiology	66
2.4.3 Molecular Genetics	41	2.9.3 Molecular Genetics	67
2.4.4 Signs and Symptoms	42	2.9.4 Symptoms and Clinical Signs	67
2.4.5 Diagnostics	42	2.9.5 Diagnostics	68
2.4.6 Staging and Classification	43	2.9.6 Staging and Classification	68
2.4.7 Treatment	43	2.9.7 Treatment	69
2.4.8 Prognosis	44	2.9.8 Prognosis	70
2.4.9 Follow-up	44	2.9.9 Follow-up	70
2.4.10 Future Perspectives	44	2.9.10 Future Perspectives	70
2.5 Liver Tumors	45	2.10 Non-rhabdomyosarcomatous Soft Tissue Sarcomas	71
2.5.1 Epidemiology	45	2.11 Germ Cell Tumors	73
2.5.2 Etiology	45	2.11.1 Epidemiology	73
2.5.3 Molecular Genetics	45	2.11.2 Etiology	73
2.5.4 Symptoms and Clinical Signs	45	2.11.3 Molecular Genetics	73
2.5.5 Diagnostics	46	2.11.4 Symptoms and Clinical Signs	73
2.5.6 Staging and Classification	47	2.11.5 Diagnostics	74
2.5.7 Treatment	48	2.11.6 Staging and Classification	75
2.5.8 Prognosis	49	2.11.7 Treatment	75
2.5.9 Follow-up	49	2.11.8 Prognosis	76
2.5.10 Future Perspectives	49	2.11.9 Follow-up	76
2.6 Neuroblastoma	50	2.11.10 Future Perspectives	77
2.6.1 Epidemiology	50	2.12 Rare Tumors	77
2.6.2 Etiology	50	2.12.1 Adrenocortical Carcinoma (ACC)	77
2.6.3 Molecular Genetics	50	2.12.2 Melanoma	77
2.6.4 Symptoms and Clinical Signs	51	2.12.3 Nasopharyngeal Carcinoma	78
2.6.5 Diagnostics	52	2.12.4 Thyroid Carcinoma	78
2.6.6 Staging and Classification	53	References	79
2.6.7 Treatment	53	Bibliography	82
2.6.8 Prognosis	55		
2.6.9 Follow-up	55		
2.6.10 Future Perspectives	57		
2.7 Renal Tumors	57		
2.7.1 Epidemiology	57		
2.7.2 Etiology	57		
2.7.3 Molecular Genetics	58		
2.7.4 Symptoms and Clinical Signs	58		
2.7.5 Diagnostics	58		
2.7.6 Staging and Classification	60		
2.7.7 Treatment	60		
2.7.8 Prognosis	60		
2.7.9 Follow-up	61		
2.7.10 Future Perspectives	61		
		3 Common Central Nervous System Tumours Nicki Fitzmaurice · Sharon Beardsmore	
		3.1 Causes/Epidemiology	86
		3.2 Distribution/Classification	86
		3.3 Staging	87
		3.4 Molecular Genetics of Brain Tumours	87
		3.5 Diagnosis	87
		3.6 Specialist Referral	89
		3.7 Hydrocephalus	89

3.8 Treatment	89	4.4 Thalassemia	118
3.8.1 Surgery	90	4.4.1 Alpha (α)-Thalassemia	118
3.8.2 Radiotherapy	90	4.4.1.1 Epidemiology	118
3.8.3 Chemotherapy	91	4.4.1.2 Etiology	118
3.9 Prognosis	91	4.4.1.3 Molecular Genetics	118
3.10 Specific Tumours	92	4.4.2 Beta (β)-Thalassemia (Cooley Anemia)	119
3.10.1 PNETs /Medulloblastomas	92	4.4.2.1 Epidemiology	119
3.10.2 Astrocytomas/Glial Tumours	93	4.4.2.2 Etiology	119
3.10.3 Malignant Gliomas	94	4.4.2.3 Molecular Genetics	119
3.10.4 Other High-grade Gliomas	95	4.4.3 Diagnostic Testing	119
3.11 Follow-up	100	4.4.4 Treatment	120
3.12 The Late Effects and Rehabilitation of Survivors	100	4.4.5 Treatment of Hemosiderosis (Iron Overload)	120
3.13 Palliative Care	100	4.4.6 Chelation Therapy	120
3.14 Future Perspectives/New Innovations	100	4.4.6.1 Initiation of Chelation Therapy	120
References	101	4.4.6.2 Chelation Regimens	121
Bibliography	101	4.4.6.3 Complications of Desferrioxamine	121
		4.4.7 Clinical Advances (Hemosiderosis)	121
		4.4.8 Prognosis	121
		4.4.9 Follow-up	121
		4.4.10 Future Perspectives	121
		4.5 Hemolytic Anemia	121
		4.5.1 Hereditary Spherocytosis (HS)	122
		4.5.1.1 Epidemiology	122
		4.5.1.2 Etiology	122
		4.5.1.3 Molecular Genetics	122
		4.5.1.4 Symptoms/Clinical Signs	122
		4.5.1.5 Diagnostic Testing	122
		4.5.1.6 Treatment	122
		4.5.1.7 Prognosis	123
		4.5.1.8 Follow-up	123
		4.5.1.9 Future Perspectives	123
		4.5.2 Autoimmune Hemolytic Anemia (AIHA)	123
		4.5.2.1 Epidemiology	123
		4.5.2.2 Etiology	123
		4.5.2.3 Molecular Genetics	123
		4.5.2.4 Symptoms/Clinical Signs	123
		4.5.2.5 Diagnostic Testing	124
		4.5.2.6 Treatment	124
		4.5.2.7 Prognosis	124
		4.5.2.8 Future Perspectives	125
		4.5.3 Glucose-6-phosphate dehydrogenase deficiency (G-6PD)	125
		4.5.3.1 Epidemiology	125
		4.5.3.2 Etiology	125
		4.5.3.3 Molecular Genetics	125
		4.5.3.4 Symptoms/Clinical Signs	126
		4.5.3.5 Diagnostic Testing	126
		4.5.3.6 Treatment	126
		4.5.3.7 Prognosis	126

PART II

4 Anemias

Rosalind Bryant

4.1 Anemia	104
4.2 Iron Deficiency Anemia	106
4.2.1 Epidemiology	106
4.2.2 Etiology	107
4.2.3 Molecular Genetics	107
4.2.4 Symptoms/Clinical Signs	107
4.2.5 Diagnostic Testing	107
4.2.6 Treatment	108
4.2.7 Transfusion	109
4.2.8 Erythropoietin (Epotin Alfa, Epogen)	109
4.2.9 Prognosis	109
4.3 Sickle Cell Disease	109
4.3.1 Epidemiology	109
4.3.2 Etiology	109
4.3.3 Molecular Genetics	110
4.3.4 Symptoms/Clinical Signs	110
4.3.5 Diagnostic Testing	110
4.3.6 Complications of SCD	111
4.3.6.1 Vaso-occlusive Crisis/Episode (VOE)	112
4.3.6.1.1 <i>Diagnostic Test/Differential</i>	112
4.3.6.1.2 <i>Treatment</i>	112
4.3.6.2 Acute Sequestration Crisis	112
4.3.6.3 Aplastic Crisis	114
4.3.6.4 Infection	114
4.3.6.5 Acute Chest Syndrome	115
4.3.6.6 Acute Abdominal Pain	116
4.3.6.7 Acute Central Nervous System Event	117
4.3.7 Preparation for Surgery	117
4.3.7.1 Hydroxyurea Therapy	118
4.3.8 Prognosis	118
4.3.9 Future Perspectives	118

4.6	Bone Marrow Failure Syndromes	126
4.6.1	Aplastic Anemia	126
4.6.1.1	Acquired Aplastic Anemia	126
4.6.1.1.1	Epidemiology	127
4.6.1.1.2	Etiology	127
4.6.1.1.3	Molecular Genetics	127
4.6.1.1.4	Symptoms/Clinical Signs	127
4.6.1.1.5	Diagnostic Testing	127
4.6.1.1.6	Treatment	128
4.6.1.1.7	Supportive Treatment	128
4.6.1.1.8	Prognosis	129
4.6.1.2	Inherited Aplastic Anemia	129
4.6.1.2.1	Epidemiology	129
4.6.1.2.2	Etiology	129
4.6.1.2.3	Molecular Genetics	129
4.6.1.2.4	Symptoms/Clinical Signs	129
4.6.1.2.5	Diagnostic Testing	129
4.6.1.2.6	Treatment	130
4.6.1.2.7	Prognosis	130
References		130

5 Neutropenia

Cara Simon

5.1	Epidemiology	133
5.2	Etiology	134
5.3	Symptoms and Clinical Signs	135
5.4	Diagnostic Testing	135
5.5	Treatment	135
5.6	Prognosis	137
5.7	Follow-up	137
Reference		137
Bibliography		137

6 Thrombocytopenia

Cara Simon

6.1	Epidemiology	139
6.2	Etiology	140
6.3	Symptoms and Clinical Signs	140
6.4	Diagnostic Testing	142
6.5	Treatment	143
6.6	Prognosis	144
6.7	Follow-up	145
6.8	Future Perspectives	145
References		145
Bibliography		145

7 Bleeding Disorders

Nicole M. Sevier

7.1	Hemophilia	147
7.1.1	Epidemiology	147
7.1.2	Etiology	147
7.1.3	Genetics	148
7.1.4	Symptoms and Clinical Signs	148
7.1.5	Diagnostic Testing	150
7.1.6	Treatment	150
7.1.7	Prognosis	153
7.1.8	Follow-Up	153
7.1.9	Future Perspectives	154
7.2	Von Willebrand Disease	154
7.2.1	Epidemiology	154
7.2.2	Etiology	154
7.2.3	Genetics	155
7.2.4	Symptoms and Clinical Signs	155
7.2.5	Diagnostic Testing	156
7.2.6	Treatment	156
7.2.7	Prognosis	159
7.2.8	Follow-up	159
References		159

PART III

8 Chemotherapy

Christine Chordas

8.1	Introduction	162
8.2	Chemotherapy Principles	162
8.2.1	Cell Cycle Phase-Specific Agents	164
8.2.2	Cell Cycle Phase-Nonspecific Agents	164
8.3	Clinical Trials	165
8.3.1	Phase I Clinical Trials	165
8.3.2	Phase II Clinical Trials	165
8.3.3	Phase III Clinical Trials	165
8.3.4	Phase IV Clinical Trials	165
8.4	Types of Chemotherapy Agents	165
8.4.1	Antimetabolites	165
8.4.1.1	Mechanism of Action	165
8.4.1.2	Side Effects	166
8.4.2	Alkylating Agents	166
8.4.2.1	Mechanism of Action	166
8.4.2.2	Side Effects	166
8.4.2.3	Long-Term Effects	167
8.4.3	Antitumor Antibiotics	167
8.4.3.1	Mechanism of Action	167
8.4.4	Plant Derivatives	167
8.4.4.1	Mechanism of Action	167

9.4	Potential side effects	198
9.5	Special considerations	199
9.5.1	Ensuring accuracy of treatment:	
	Patient issues	199
9.5.1.1	Marking	199
9.5.1.2	Patient immobilisation	199
9.5.1.3	Sedation and general anaesthesia	199
9.5.1.4	Preparation of children and young people	200
9.5.2	Brachytherapy	200
9.5.3	Unsealed sources of radiation treatment	200
9.6	Future Perspectives	200
	References	200

10 Hematopoietic Stem Cell Transplantation

Robbie Norville

10.1	Principles of Treatment	201
10.2	Description of Treatment	204
10.2.1	Stem Cell Collection (Harvest)	205
10.3	Potential Side Effects	207
10.3.1	Early Side Effects	207
10.3.2	Intermediate Side Effects	210
10.3.3	Late Side Effects	212
10.4	Special Considerations	215
10.5	Future Perspectives	216
	References	216
	Bibliography	216

11 Surgical Approaches to Childhood Cancer

Jill Brace O'Neill

11.1	Principles of Treatment	219
11.2	Description of Treatment	219
11.3	Method of Delivery	220
11.3.1	Preoperative Evaluation	220
11.3.2	Postoperative Nursing Care	221
11.4	Potential Side Effects	222
11.4.1	Complications of Medical Therapy Requiring Surgical Evaluation	222
11.4.2	Complications Arising from Surgical Management of Solid Tumors	223
11.5	Special Considerations	223
11.5.1	Vascular Access Devices	223
11.6	Future Perspectives	224
11.6.1	New Surgical Techniques and Directions for Future Research	224
	References	225
	Bibliography	225

12 Gene Therapy

Kathleen E. Houlahan · Mark W. Kieran

12.1	Introduction	227
12.2	Principles of Treatment	228
12.3	Method of Delivery	229
12.4	Potential Side Effects	230
12.5	Special Considerations	230
12.6	Future Perspectives	231
	References	231

13 Complementary and Alternative Therapy

Nancy E. Kline

13.1	Principles of Treatment	233
13.2	Description of Treatment	234
13.3	Method of Delivery	234
13.3.1	Alternative Medical Systems	234
13.3.2	Mind–Body Interventions	234
13.3.3	Biologically Based Treatments	235
13.3.4	Body Manipulation	235
13.3.5	Energy Therapies	235
13.4	Potential Side Effects	235
13.5	Special Considerations	237
13.6	Future Perspectives	238
	References	238

PART IV

14 Metabolic System

Deborah Tomlinson

14.1	Cancer Cachexia	239
14.1.1	Incidence	239
14.1.2	Etiology	240
14.1.3	Treatment	240
14.1.4	Prognosis	240
14.2	Obesity	241
14.2.1	Incidence	241
14.2.2	Etiology	241
14.2.3	Treatment	241
14.2.4	Prognosis	241
14.3	Tumour Lysis Syndrome	242
14.3.1	Incidence	242
14.3.2	Etiology	242
14.3.3	Treatment	244
14.3.3.1	Patient Assessment	244
14.3.3.2	Preventative Measures	245
14.3.3.3	Management of Metabolic Abnormalities	246
14.3.4	Prognosis	247

14.4 Hypercalcaemia	247
14.4.1 Incidence	247
14.4.2 Etiology	247
14.4.3 Treatment	248
14.4.4 Prognosis	248
14.5 Impaired Glucose Tolerance	
Following Bone Marrow Transplant	249
14.5.1 Incidence	249
14.5.2 Etiology	249
14.5.3 Treatment	249
14.5.4 Prognosis	249
References	249

15 Gastrointestinal Tract

Anne-Marie Maloney

15.1 Mucositis	252
15.1.1 Incidence	252
15.1.2 Etiology	252
15.1.2.1 Iatrogenic	252
15.1.2.2 Bacterial	254
15.1.2.3 Viral	254
15.1.2.4 Fungal	254
15.1.3 Prevention	254
15.1.4 Treatment	254
15.1.5 Prognosis	255
15.2 Dental Caries	255
15.2.1 Incidence	255
15.2.2 Etiology	255
15.2.2.1 Iatrogenic	255
15.2.3 Prevention and Treatment	255
15.2.4 Prognosis	256
15.3 Nausea and Vomiting	256
15.3.1 Incidence	256
15.3.2 Etiology	256
15.3.3 Prevention	258
15.3.4 Treatment	258
15.3.4.1 Delayed Nausea and Vomiting	259
15.3.4.2 Anticipatory Nausea and Vomiting	260
15.3.4.3 Radiation-Induced Nausea and Vomiting	260
15.3.4.4 Other Causes of Nausea and Vomiting	260
15.3.4.5 Nonpharmacological Management	260
15.3.5 Prognosis	260
15.4 Constipation	260
15.4.1 Incidence	260
15.4.2 Etiology	261
15.4.2.1 Iatrogenic	261
15.4.2.2 Primary Constipation	261
15.4.2.3 Secondary Constipation	261
15.4.3 Prevention	261
15.4.4 Treatment	262
15.4.5 Prognosis	263
15.5 Diarrhoea	263
15.5.1 Incidence	263
15.5.2 Etiology	264
15.5.2.1 Iatrogenic	264
<i>Chemotherapy</i>	264
<i>Radiation</i>	264
<i>Other Iatrogenic Cause of Diarrhoea</i>	264
15.5.2.2 Fungal	264
15.5.2.3 Viral	264
15.5.2.4 Bacterial	265
15.5.2.5 Other Infectious Aetiologies of Diarrhoea	265
15.5.3 Prevention	265
15.5.4 Treatment	265
15.5.5 Prognosis	266
15.6 Typhlitis	266
15.6.1 Incidence	266
15.6.2 Etiology	266
15.6.2.1 Iatrogenic	266
15.6.2.2 Fungal	266
15.6.2.3 Viral	266
15.6.2.4 Bacterial	267
15.6.3 Prevention	267
15.6.4 Treatment	267
15.6.5 Prognosis	267
15.7 Perirectal Cellulitis	267
15.7.1 Incidence	267
15.7.2 Etiology	268
15.7.2.1 Iatrogenic	268
15.7.2.2 Bacterial	268
15.7.3 Prevention	268
15.7.4 Treatment	268
15.7.5 Prognosis	268
15.8 Acute Gastrointestinal Graft Versus Host Disease	268
15.8.1 Incidence	268
15.8.2 Prevention	269
15.8.3 Treatment	269
15.8.4 Prognosis	270
15.9 Chemical Hepatitis	270
15.9.1 Incidence	270
15.9.2 Etiology	270
15.9.3 Prevention	270
15.9.4 Treatment	270
15.9.5 Prognosis	271
References	271

16 Bone Marrow

Sandra Doyle

16.1 Anemia	274
16.1.1 Incidence and Etiology	274
16.1.2 Treatment	274
16.1.2.1 Transfusion	274
16.1.2.2 Use of Recombinant Human Erythropoietin	275
16.2 Neutropenia	275
16.2.1 Incidence and Etiology	275
16.2.1.1 Fever (Pyrexia) and Neutropenia	275
16.2.2 Treatment	276
16.2.2.1 Antibiotic Management	277
16.2.2.2 Special Consideration for the Management of Indwelling Intravenous Catheters	278
16.2.2.3 Management of Candidiasis (Oropharyngeal Candidiasis and <i>Candida</i> Esophagitis)	278
16.2.2.4 Infections Due to <i>Aspergillus</i> Species	278
16.2.2.5 Management of Viral Infections	278
16.2.2.6 Infections Due to <i>Pneumocystis jiroveci</i> (Formerly <i>Pneumocystis carinii</i>)	280
16.2.2.7 Use of Colony Stimulating Factors (CSF) in Children with Neutropenia	280
16.2.2.8 Isolation	280
16.3 Thrombocytopenia	281
16.3.1 Incidence and Etiology	281
16.3.2 Treatment	281
16.4 Transfusion Issues	281
16.4.1 Granulocyte Transfusions	281
16.4.2 Transfusion-associated Graft-Versus-Host Disease	282
16.4.3 Cytomegalovirus and Transfusions	282
16.4.3.1 Treatment	282
16.4.4 Platelet Refractoriness	283
16.4.4.1 Treatment	283
16.5 Disseminated Intravascular Coagulation	283
16.5.1 Etiology and Manifestation	284
16.5.1.1 Diagnosis	285
16.5.2 Treatment	285
16.6 Septic Shock	285
16.6.1 Etiology	285
16.6.2 Treatment	286
16.6.3 Prognosis	286

16.7 Immune Suppression	286
16.7.1 Polymorphonuclear Leukocytes	286
16.7.2 Lymphocytes	287
16.7.3 Spleen and Reticuloendothelial System	287
16.7.4 Other Factors Contributing to Immunocompromised States	288
References	288

17 Respiratory System

Margaret Parr

17.1 <i>Pneumocystis</i> Pneumonia	291
17.1.1 Incidence	291
17.1.2 Etiology	291
17.1.3 Prevention	292
17.1.4 Treatment	292
17.1.5 Prognosis	294
17.2 Pneumonitis	294
17.2.1 Incidence	294
17.2.2 Etiology	294
17.2.3 Prevention	295
17.2.4 Treatment	295
17.2.5 Prognosis	295
17.3 Fibrosis	295
17.3.1 Incidence	295
17.3.2 Etiology	296
17.3.3 Prevention	296
17.3.4 Treatment	296
17.3.5 Prognosis	296
17.4 Compromised Airway	296
17.4.1 Incidence	296
17.4.2 Etiology	296
17.4.3 Prevention	297
17.4.4 Treatment	297
17.4.5 Prognosis	298
References	298

18 Renal System

Fiona Reid

18.1 Nephrectomy	302
18.1.1 Incidence	302
18.1.2 Etiology	302
18.1.2.1 Neoplasms	302
18.1.2.2 Bacterial	302
18.1.3 Treatment	302
18.1.3.1 Preoperative	302
18.1.3.2 Surgery	303
18.1.3.3 Postoperative Care	305
18.1.4 Prognosis	305

18.2 Cytotoxic Drug Excretion	306
18.2.1 Pharmacokinetics/Dynamics	307
18.2.2 Metabolism	307
18.2.3 Excretion	309
18.2.4 Drug Interactions	311
18.2.5 Dose Modification	311
18.2.6 Safe Handling of Cytotoxic Excreta	312
18.3 Nephrotoxicity	313
18.3.1 Incidence	313
18.3.2 Etiology	314
18.3.2.1 Iatrogenic	314
<i>Radiation</i>	314
<i>Chemicals</i>	314
18.3.2.2 Fungal	314
18.3.2.3 Viral	316
18.3.2.4 Bacterial	316
18.3.3 Prevention	316
18.3.4 Treatment	316
18.3.4.1 Fluid Overload	318
18.3.4.2 Metabolic Acidosis	318
18.3.4.3 Electrolyte Imbalance	318
18.3.5 Prognosis	318
18.4 Hemorrhagic Cystitis	319
18.4.1 Incidence	319
18.4.2 Etiology	320
18.4.2.1 Iatrogenic	320
<i>Radiation</i>	320
<i>Chemical</i>	320
18.4.2.2 Fungal	320
18.4.2.3 Viral	321
18.4.2.4 Bacterial	321
18.4.3 Prevention	321
18.4.4 Treatment	322
18.4.5 Prognosis	323
References	324

19 Cardiovascular System

Ali Hall

19.1 Cardiotoxicity/Cardiomyopathy	327
19.1.1 Incidence	327
19.1.1.1 On Treatment Recommendations	328
19.1.1.2 Modification Therapy	328
19.1.2 Etiology	328
19.1.3 Treatment	331
19.1.4 Prevention	331
19.1.4.1 Limiting the Effects of Myocardial Concentrations of Anthracyclines and Their Metabolites	331
19.1.4.2 Concurrent Administration of Cardioprotective Agents	332
19.1.4.3 Developing Less Cardiotoxic Therapies	332
19.1.4.4 Lifestyle Advice	332
<i>Guidelines for Long-term Follow-up Post-completion of Anthracycline Therapy</i>	332
19.1.5 Prognosis	332
19.2 Veneno-occlusive Disease	332
19.2.1 Hepatic Veneno-occlusive Disease	332
19.2.1.1 Incidence	333
19.2.1.2 Diagnostic Tests	333
19.2.1.3 Etiology	333
19.2.1.4 Treatment	334
19.2.1.5 Prevention	334
19.2.1.6 Prognosis	335
19.2.2 Pulmonary Veneno-occlusive Disease	335
19.2.2.1 Incidence	335
19.2.2.2 Etiology	335
19.2.2.3 Treatment	335
19.2.2.4 Diagnosis	335
19.2.2.5 Prognosis	335
References	336
Bibliography	336

20 Central Nervous System

Jane Belmore · Deborah Tomlinson

20.1 Spinal Cord Compression	337
20.1.1 Incidence	337
20.1.2 Etiology	337
20.1.3 Treatment	338
20.1.4 Prognosis	338
20.2 Fatigue	338
20.2.1 Incidence	338
20.2.2 Etiology	339
20.2.3 Treatment	340
20.2.4 Prognosis	340
20.3 Cognitive Deficits	341
20.3.1 Incidence	341
20.3.2 Etiology	342
20.3.3 Treatment	342
20.3.4 Prognosis	342
20.4 Diabetes Insipidus	343
20.4.1 Incidence	343
20.4.2 Etiology	343
20.4.3 Treatment	343
20.4.4 Prognosis	343
References	343

21 Musculoskeletal System

Chris M. Senter · Deborah Tomlinson

21.1 Limb Salvage Procedures	345
21.1.1 Incidence	345
21.1.2 Procedure	345
21.1.2.1 Management	348
21.2 Amputation	348
21.2.1 Incidence	348
21.2.2 Procedure	349
21.2.3 Rotationplasty	349
21.2.3.1 Management	349
21.2.3.2 Comparison of Limb Salvage and Amputation	350
<i>Duration of Survival</i>	350
<i>Immediate and Ultimate Morbidity</i>	350
<i>Function</i>	350
<i>Quality of Life</i>	351
21.3 Altered Bone Density and Increased Risk of Fracture	351
21.3.1 Incidence	351
21.3.2 Etiology	351
21.3.3 Treatment	352
21.3.4 Prognosis	352
References	352

22 Skin

Cutaneous Toxicities

Deborah Tomlinson · Nan D. McIntosh

22.1 Alopecia	355
22.1.1 Incidence	355
22.1.2 Etiology	355
22.1.3 Treatment	356
22.1.4 Prognosis	356
22.2 Altered Skin Integrity Associated with Radiation Therapy	357
22.2.1 Incidence	357
22.2.2 Etiology	357
22.2.3 Prevention	357
22.2.4 Treatment	358
22.2.5 Prognosis	358
22.3 Radiation Sensitivity and Recall	358
22.3.1 Incidence	358
22.3.2 Etiology	358
22.3.3 Treatment	359
22.3.4 Prognosis	359
22.4 Photosensitivity	359

22.5 Cutaneous Reactions Associated with High-dose Cytosine Arabinoside	359
22.5.1 Incidence	359
22.5.2 Etiology	359
22.5.3 Prevention and Treatment	359
22.6 Nail Dystrophies	360
22.7 Graft Versus Host Disease	360
22.7.1 Incidence and Etiology	360
22.7.2 Treatment	361
22.7.3 Prevention	362
22.7.4 Treatment	362
22.7.5 Prognosis	362
References	363

23 Endocrine System

Deborah Tomlinson · Ethel McNeill

23.1 Hypothalamic-Pituitary Dysfunction	365
23.1.1 Incidence and Etiology	365
23.2 Growth Hormone Deficiency	366
23.2.1 Treatment	367
23.2.1.1 Investigation	367
23.2.1.2 Growth Hormone Replacement Therapy	367
23.2.2 Prognosis	367
23.3 Hypothalamic-Pituitary-Gonadal Axis	367
23.3.1 Gonadotrophin Deficiency	367
23.3.2 Early or Precocious Puberty	368
23.3.2.1 Treatment	368
23.3.2.2 Prognosis	368
23.4 Thyroid Disorders	369
23.4.1 Treatment	369
23.5 Hypothalamic-Pituitary-Adrenal Axis	369
23.6 Other Pituitary Hormones	370
23.6.1 Fertility	370
23.6.1.1 Testicular Failure	370
23.6.1.2 Ovarian Failure	370
23.6.2 Treatment	370
23.6.2.1 Assessment of Gonadal Function	370
23.6.2.2 Treatment for Gonadal Dysfunction	370
23.6.3 Prognosis	371
References	373

24 Otototoxicity

Colleen Nixon

24.1 Incidence	375
24.2 Prevention and Treatment	378
References	381

25 Eyes – Ocular complications

Deborah Tomlinson

25.1 Ocular Toxicity Associated with High-dose Cytarabine Arabinoside	383
25.1.1 Incidence and Etiology	383
25.1.2 Prevention	384
25.1.3 Treatment	384
25.1.4 Prognosis	384
25.2 Cataracts	384
25.2.1 Incidence	384
25.2.2 Etiology	384
25.2.3 Prevention	385
25.2.4 Treatment	385
25.2.5 Prognosis	385
References	385

PART V**26 Nutrition and Hydration in Children with Cancer**

Elizabeth Kassner

26.1 Introduction	387
26.2 Principles of Treatment	388
26.2.1 Nutritional Assessment	388
26.3 Method of Delivery	389
26.3.1 Oral and Enteral Replacement Strategies	389
26.3.2 Selection of Supplemental Enteral Nutritional Solutions	389
26.4 Special Considerations	390
26.4.1 Common Complications of Oral/Enteral Nutritional Supplementation	390
26.4.2 Total Parental Nutrition (TPN)/Hyperalimentation	391
26.4.3 Complications of TPN/Hyperalimentation	393
26.4.4 Glutamine	393
26.4.5 Intravenous Fluid and Electrolyte Requirements	393
26.4.6 Specific Nutritional Concerns During Palliative Care	394
References	396
Bibliography	396

27 Pain in Children with Cancer

Debbie Rembert

27.1 Introduction	397
27.2 Causes of Pain in Childhood Cancer	398
27.3 Assessment	398
27.4 Cultural Issues	402
27.5 Principles of Treatment	404
27.6 Treatment	404
27.6.1 By the Ladder	404
27.6.1.1 Step I: Mild Pain	404
27.6.1.2 Step II: Mild to Moderate Pain	405
27.6.1.3 Step III: Moderate to Severe Pain	405
27.6.1.4 Step IV: Intractable Pain	405
27.6.2 By the Route	408
27.6.3 By the Clock	409
27.6.4 Opioids	409
27.6.5 Equianalgesia	409
27.6.6 Procedure-related Pain	409
27.6.7 Patient-controlled Analgesia (PCA)	410
27.6.8 Adjuvant Medications	410
27.6.9 Nonpharmacologic Treatment	410
27.7 Summary	411
References	412
Bibliography	412

28 Blood Transfusion Therapy

Elizabeth Kassner

28.1 Introduction	414
28.2 Blood Screening Guidelines	414
28.2.1 Blood Product Processing	415
28.3 Transfusion Complications	416
28.3.1 Hemolytic Reactions	416
28.3.2 Nonhemolytic Reactions	417
28.3.3 Allergic Reactions	417
28.3.4 Graft Versus Host Disease (GvHD)	417
28.3.5 Fluid Overload	418
28.3.6 Transfusion-acquired Infections	418
28.3.6.1 Bacterial Infections	418
28.3.6.2 Cytomegalovirus (CMV)	418
28.4 Erythrocyte Transfusion	419
28.4.1 Erythrocyte Transfusion Options	420
28.4.2 Special Transfusion Considerations	420
28.4.2.1 Partial Exchange Transfusion	420
28.4.2.2 Specific Risks of Erythrocyte Transfusion	420
28.5 Platelet Transfusion Options	420
28.5.1 Procurement and Storage	421
28.5.2 Transfusion Guidelines	421
28.5.3 Dosing Recommendations	421
28.5.4 Infusion Guidelines	421

28.5.5	Platelet-specific Transfusion Risks	421
28.5.6	Platelet Alloimmunization	421
28.5.7	Treatment Options	421
28.6	Granulocyte Transfusion	421
28.6.1	Indications	422
28.6.2	Dosing Guidelines	422
28.6.3	Specific Risks	422
28.7	Albumin	422
28.7.1	Volume	422
28.7.2	Transfusion	422
28.8	Fresh Frozen Plasma (FFP)	422
28.8.1	Indications	422
28.8.2	Volume	422
28.8.3	Transfusion	422
28.9	Cryoprecipitate	423
28.9.1	Indications	423
28.9.2	Volume	423
28.9.3	Transfusion	423
28.10	Intravenous Immunoglobulin (IVIG)	423
28.10.1	Indications	423
28.10.2	Volume	423
28.10.3	Side Effects	423
28.11	Recombinant Human (rHu) Erythropoietin Alpha	423
28.12	Palliative Care Issues for Transfusion Therapy	423
28.12.1	Erythrocyte Transfusion	423
28.12.2	Platelet Transfusion	423
	References	424
	Bibliography	424

29 Growth Factors

Nancy E. Kline

29.1	Principles of Treatment	425
29.2	Method of Delivery	427
29.3	Future Perspectives	428
	References	429

30 Care of the Dying Child and the Family

Angela M. Ethier

30.1	Children's Understanding of Death	431
30.1.1	Infants and Toddlers (0–36 Months)	431
30.1.2	Preschool Children (3–5 Years)	431
30.1.3	School-age Children (6–12 Years)	433
30.1.4	Adolescents (13–20 Years)	433
30.2	Explaining Death to Children	433
30.3	Pediatric Palliative Care	433
30.3.1	Principles	433
30.3.2	Location of Care	434
30.4	Grief	434
30.4.1	Principles	434
30.4.2	Assessment of Child and Family	436
30.4.3	Interventions	436
30.5	Cultural and Spiritual Care	438
30.5.1	Principles	438
30.5.2	Assessment of Child and Family	438
30.5.3	Interventions	438
30.6	Bereavement	439
30.6.1	Principles	439
30.6.2	Assessment of Child and Family	440
30.6.3	Interventions	440
30.7	Resources	440
30.7.1	Resources for Children	440
30.7.2	Resources for Adults	441
	References	441
	Bibliography	442

Subject Index	443
--------------------------------	------------